GlassScriptPhysician profile
Michael S Schurdell
NPI 1407148091
$1,640.61
in general payments reported to CMS, 2019-2025
23 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $414 · 2021: $423 · 2022: $130 · 2023: $63.05 · 2024: $141 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $288.72 | 2020 | |
| Medtronic, INC. | $251.12 | 2021-2023 | Intellis Adaptivestim |
| Abbott Laboratories | $200.51 | 2019-2025 | Eterna, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.10 | 2019-2025 | Relistor |
| Atland Pharmaceuticals, LLC | $74.37 | 2024-2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Biodelivery Sciences International, INC. | $60.74 | 2019-2021 | |
| Depuy Synthes Sales INC. | $55.15 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $53.34 | 2021 | |
| Pfizer INC. | $53.22 | 2019-2020 | |
| Daiichi Sankyo INC. | $52.66 | 2019 | |
| Tersera Therapeutics LLC | $43.58 | 2019 | |
| Abbvie INC. | $42.75 | 2021-2022 | |
| Orthogenrx INC. | $41.72 | 2019-2020 | |
| Nevro Corp. | $35.04 | 2019-2021 | |
| Boston Scientific Corporation | $33.92 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $28.65 | 2023-2024 | Xtampza |
| Novartis Pharmaceuticals Corporation | $25.65 | 2019-2020 | |
| Averitas Pharma INC. | $23.70 | 2025 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $18.83 | 2022 | |
| Tonix Medicines, INC. | $17.61 | 2025 | Tonmya |
| Biohaven Pharmaceuticals, INC. | $16.09 | 2020 | |
| Nalu Medical, INC. | $13.45 | 2022 | |
| Protega Pharmaceutials INC | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schurdell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.